Introduction
Highlight
- Effective coordination of multidisciplinary teams across regulatory, ethical, financial, and clinical domains is critical for successful cardiac xenotransplant implementation.
- Securing Food and Drug Administration (FDA) authorization necessitates comprehensive institutional planning and continuous dialogue with regulatory bodies.
- Ethical patient selection and consent processes prioritize transparency, patient autonomy, and public health safeguards.
- Institutional experiences provide a replicable administrative framework supporting future xenotransplantation initiatives.
Specialty calculators
For clinical reference; use professional judgment.
